Skip to Main Content

Paper Details

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.
Cell Rep
61
2014
BRAF, BRAF-mutant cancer, BRAF-mutant cancer cells, BRAF-mutant cells, IL-6, JAK, MAPK, MEK, Oncogene, RAF, RAS, STAT3, cell lines, interleukin-6, mitogen-activated protein kinase, oncogenic RAS, patients, primary resistant BRAF-mutant cells, tumors, vemurafenib
Author NameAffiliation
Martin L SosUniversity of California san francisco
Rebecca S LevinUniversity of California, USA Department of Pharmaceutical Chemistry san francisco
John D GordanUniversity of California, Helen Diller Family Comprehensive Cancer Center san francisco
Juan A Oses-PrietoDepartment of Pharmaceutical Chemistry, University of California san francisco
James T WebberUniversity of California san francisco
Alma L BurlingameDepartment of Pharmaceutical Chemistry, University of California san francisco
Alma L BurlingameDepartment of Pharmaceutical Chemistry, University of California san francisco
Frank McCormickHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Sourav BandyopadhyayUniversity of California san francisco
Kevan M ShokatUniversity of California san francisco
  • 1 - 10

Datasets